Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(01): 1-3
DOI: 10.4103/0971-5851.176979
EDITORIAL COMMENTARY

Molecular functional imaging in personalized clinical oncology: The road less traveled

Abhishek Mahajan
Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Subhash Desai
Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Ameya Kawthalkar
Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Meenakshi Thakur
Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
12 July 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Mahajan A, Goh V, Basu S, Vaish R, Weeks AJ, Thakur MH, et al. Bench to bedside molecular functional imaging in translational cancer medicine: To image or to imagine? Clin Radiol 2015;70:1060-82.
  • 2 Dhingra VK, Mahajan A, Basu S. Emerging clinical applications of PET based molecular imaging in oncology: The promising future potential for evolving personalized cancer care. Indian J Radiol Imaging 2015;25:332-41.
  • 3 Kalia M. Biomarkers for personalized oncology: Recent advances and future challenges. Metabolism 2015;64 3 Suppl 1:S16-21.
  • 4 Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
  • 5 O′Connor JP, Jackson A, Asselin MC, Buckley DL, Parker GJ, Jayson GC. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: Current and future perspectives. Lancet Oncol 2008;9:766-76.
  • 6 Mahajan A, Engineer R, Chopra S, Mahanshetty U, Juvekar SL, Shrivastava SK, et al. Role of 3T multiparametric-MRI with BOLD hypoxia imaging for diagnosis and post therapy response evaluation of postoperative recurrent cervical cancers. European Journal of Radiology Open, 3, 2016. p. 22-30.
  • 7 Mahajan A, A V Moiyadi, R Jalali, E Sridhar. Radiogenomics of glioblastoma: a window into its imaging and molecular variability. Cancer Imaging 10/2015; 15 (Suppl 1): p. 14. DOI:10.1186/1470-7330-15-S1-P14.
  • 8 Fleuren ED, Versleijen-Jonkers YM, Heskamp S, van Herpen CM, Oyen WJ, van der Graaf WT, et al. Theranostic applications of antibodies in oncology. Mol Oncol 2014;8:799-812.
  • 9 Katz R. Biomarkers and surrogate markers: An FDA perspective. NeuroRx 2004;1:189-95.
  • 10 NIH-FDA Conference: Biomarkers and surrogate endpoints: Advancing clinical research and applications. Abstracts. Dis Markers 1998;14:187-334.
  • 11 Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-15.